Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594729 | 0.88 | HSP90AA1 (0.41) | HSP90AA1CTSSCTSKNR1H2FASN | |
| SCHEMBL3597545 | 0.88 | AR (0.39) | HSP90AA1POLB | |
| SCHEMBL13404301 | 0.82 | POLB (0.52) | POLB | |
| SCHEMBL3598966 | 0.80 | AR (0.40) | POLB | |
| SCHEMBL3911826 | 0.77 | KDM4E (0.37) | POLB | |
| SCHEMBL3609964 | 0.76 | KDM4E (0.42) | POLB | |
| SCHEMBL3597829 | 0.74 | AR (0.35) | POLB | |
| SCHEMBL3599843 | 0.73 | AR (0.40) | POLBPOLQ | |
| SCHEMBL11555312 | 0.72 | BRD4 (0.36) | HSP90AA1HSP90B1TRAP1POLBCTSS | |
| SCHEMBL3597635 | 0.71 | ALDH1A1 (0.39) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | HSP90AA1 4335/4885HSP90B1 4001/4885TRAP1 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.